BRPI0507916A - moduladores de oxidecahidronaftaleno de hm74 - Google Patents

moduladores de oxidecahidronaftaleno de hm74

Info

Publication number
BRPI0507916A
BRPI0507916A BRPI0507916-0A BRPI0507916A BRPI0507916A BR PI0507916 A BRPI0507916 A BR PI0507916A BR PI0507916 A BRPI0507916 A BR PI0507916A BR PI0507916 A BRPI0507916 A BR PI0507916A
Authority
BR
Brazil
Prior art keywords
modulators
oxidecahydronaphthalene
oxidecaline
oxidecahydrophylene
molecules
Prior art date
Application number
BRPI0507916-0A
Other languages
English (en)
Inventor
Anne Minnich
Theresa Kuntzweiler
Haifeng Eishingdrelo
Michael Angelastro
Stephan Henke
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0507916A publication Critical patent/BRPI0507916A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MODULADORES DE OXIDECAHIDRONAFTALENO DE HM74. Céluas hospedeiras expressando HM74 f oram usadas para obter moléculas similares a oxidecalina com atividade agonista tendo a estrutura a seguir (fórmula I)
BRPI0507916-0A 2004-02-20 2005-02-10 moduladores de oxidecahidronaftaleno de hm74 BRPI0507916A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54601204P 2004-02-20 2004-02-20
PCT/US2005/004095 WO2005082352A1 (en) 2004-02-20 2005-02-10 Oxydecahydronaphthalene modulators of hm74

Publications (1)

Publication Number Publication Date
BRPI0507916A true BRPI0507916A (pt) 2007-07-10

Family

ID=34910747

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507916-0A BRPI0507916A (pt) 2004-02-20 2005-02-10 moduladores de oxidecahidronaftaleno de hm74

Country Status (21)

Country Link
US (2) US7264937B2 (pt)
EP (1) EP1718293A1 (pt)
JP (1) JP2007526917A (pt)
KR (1) KR101145693B1 (pt)
CN (1) CN1929833A (pt)
AR (1) AR047708A1 (pt)
AU (1) AU2005216878B2 (pt)
BR (1) BRPI0507916A (pt)
CA (1) CA2556757C (pt)
CR (1) CR8537A (pt)
EC (1) ECSP066776A (pt)
IL (1) IL177106A (pt)
MA (1) MA28368A1 (pt)
ME (2) MEP17008A (pt)
NO (1) NO20064214L (pt)
RS (1) RS20060472A (pt)
RU (1) RU2006133539A (pt)
TN (1) TNSN06235A1 (pt)
TW (1) TWI354552B (pt)
WO (1) WO2005082352A1 (pt)
ZA (1) ZA200606687B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) * 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
CA2589483C (en) 2004-12-03 2013-10-29 Schering Corporation Substituted piperazines as cb1 antagonists
BRPI0706623A2 (pt) * 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
MX2010000334A (es) * 2007-06-28 2010-04-22 Intervet Int Bv Piperazinas sustituidas como antagonistas de cannabinoides 1.
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
DE19624154A1 (de) * 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU7966098A (en) * 1997-06-12 1998-12-30 Smithkline Beecham Corporation Hm74a receptor
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Also Published As

Publication number Publication date
CR8537A (es) 2007-03-05
ECSP066776A (es) 2006-11-16
NO20064214L (no) 2006-09-18
RS20060472A (en) 2008-11-28
ZA200606687B (en) 2008-02-27
ME00059B (me) 2010-06-10
IL177106A (en) 2012-03-29
CA2556757A1 (en) 2005-09-09
AU2005216878B2 (en) 2010-06-17
CN1929833A (zh) 2007-03-14
IL177106A0 (en) 2006-12-10
US20080045586A1 (en) 2008-02-21
AR047708A1 (es) 2006-02-08
AU2005216878A1 (en) 2005-09-09
EP1718293A1 (en) 2006-11-08
WO2005082352A1 (en) 2005-09-09
KR20060127982A (ko) 2006-12-13
US20050187263A1 (en) 2005-08-25
TW200539864A (en) 2005-12-16
US7264937B2 (en) 2007-09-04
CA2556757C (en) 2011-05-03
RU2006133539A (ru) 2008-03-27
JP2007526917A (ja) 2007-09-20
MEP17008A (en) 2010-06-10
KR101145693B1 (ko) 2012-05-25
TWI354552B (en) 2011-12-21
MA28368A1 (fr) 2006-12-01
TNSN06235A1 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
ECSP10010222A (es) Toalla para llevar puesta
ECSP066637A (es) Biaril sulfonamidas y métodos para su uso
NO20064237L (no) Furosemide modulatorer for HM74
ECSP088352A (es) Derivados de indol 1,3-disustituido para su uso como moduladores de ppar
ECSP077271A (es) Derivados de pirimidina
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
NI200500164A (es) Nueva difenilazetidinona con caracteristicas fisiologicas mejoradas, correspondiente metodo de produccion, medicamentos que contienen dicho compuesto y su uso.
ECSP077259A (es) Derivados de pirimidina
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
CR10157A (es) Compuestos químicos
CY1109414T1 (el) Ν-σουλφονυλ πυρρολια και χρηση αυτων ως αναστολεις αποακετυλασης ιστονης
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
PT1440666E (pt) Braco com uniao rotativa para tabuleiro cirurgico
DK1735286T3 (da) Tetrahydroindazoler som cannabinoidmodulatorer
DE602004010791D1 (de) 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
BRPI0507916A (pt) moduladores de oxidecahidronaftaleno de hm74
NO20065907L (no) Nye tetrahydropyridotiofener
CR11463A (es) Compuestos de piridilmetil-sulfonamida
DK1931636T3 (da) Isoquinoliner som IGF-1R-inhibitorer
EA200702290A1 (ru) Мотилидные соединения
UY28344A1 (es) Nuevos compuestos
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
PA8646301A1 (es) Inhibidores de la adenilato ciclasa soluble
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]